Novartis agrees U.S. label change for Gilenya

ZURICH, April 20 (Reuters) - Novartis said it had
agreed with the U.S. Food and Drug Administration on label
changes for multiple sclerosis drug Gilenya to include a
recommendation that patients are more closely monitored for
heart problems.

aib investment managers structured settlement consultants company settlement structured